Abcam, ab228462, Anti-PD-L1 antibody [SP142] - C-terminal

Size: 20µL / 100µL / 500µL / 1mL
Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) is a rabbit monoclonal antibody detecting PD-L1 in IHC-P, ICC/IF, mIHC . Suitable for Human . - Multiplex IHC validated on the Leica BOND® MAX using Opal reagents - Biophysical QC for unrivalled batch-batch consistency - Over 90 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:SP142,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, ICC/IF, mIHCSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC-P and mIHC.
Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) was first used in a scientific publication in 2016 and has been cited over 95 times in peer reviewed journals. It's performance in IHC in human and mouse samples is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 32kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL, 500 µL and 1 mL).
Conjugation-ready, carrier free format available for antibody clone SP142 -
ab236238
Antibody clone SP142 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor
647, Alexa Fluor
488, Alexa Fluor
594, Alexa Fluor
568, Alexa Fluor
555, Alexa Fluor
ab267563
ab310995
ab311750
ab313030
ab313231
ab321463
Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) is a clone from the portfolio of Spring Bioscience (Roche) SP clones which have been optimised for immunohistochemistry (IHC).
PD-L1 allows tumors to escape immune detection by binding to the PD-1 receptor on T-cells, suppressing their function. Blocking this interaction with immune checkpoint inhibitors reactivates T-cells, enabling them to attack cancer cells.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A/G, Purification notes-Purified from TCS by protein A/G., Storage buffer-pH: 7.6Preservative: 0.1% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as programmed death-ligand 1 or CD274 plays an important role in the immune system. It is a protein expressed on antigen-presenting cells and some tumor cells helping them interact with T-cells. The molecular weight of PD-L1 is approximately 33 kDa. PD-L1 expression can occur in various tissues and is often upregulated in tumor microenvironments. This increased expression helps tumors evade the immune response.
Biological function summary
PD-L1 modulates the immune response by interacting with its receptor PD-1 on T-cells and other immune cells leading to immune suppression. It is part of the PD-1/PD-L1 complex an important regulator of T-cell activity and immune tolerance. The binding of PD-L1 to PD-1 inhibits T-cell proliferation and cytokine production reducing the ability of the immune system to attack cancer cells.
Pathways
PD-L1 is involved in the immune checkpoint pathway and the cancer immunity cycle. Its interaction with PD-1 influences important signaling cascades within these pathways affecting the immune system's capacity to target tumor cells effectively. Another protein important in this context is CTLA-4 another immune checkpoint regulator which along with PD-1 modulates immune system activity against cancer.
PD-L1 has strong connections to cancer and autoimmune diseases. Many cancers including melanoma and non-small cell lung cancer exploit PD-L1 to protect themselves from the immune system. Increased PD-L1 expression can also impact autoimmune disorders where the immune system reacts against healthy body tissues. This interaction further involves PD-1 and CTLA-4 illustrating their shared roles in these disease contexts.